Market Research Logo

Ischemic Heart Disease (IHD) Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2019-2024

Ischemic Heart Disease (IHD) Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2019-2024

The global ischemic heart disease (IHD) drugs market is expected to grow at a CAGR of around 3% during 2019-2024. Ischemic heart disease (IHD), also known as coronary heart disease, is a condition that damages the heart muscle by interrupting the oxygen and blood supply. It involves molecular changes in the blood vessels or sudden closure and narrowing of coronary arteries by atheroma. The disease is often characterized by chronic chest pain and severe discomfort and can be fatal if left untreated. Various drugs are used to treat IHD depending on the intensity of the case. For instance, if cholesterol-modifying medication decreases cholesterol levels in the blood, then aspirin is prescribed to reduce clotting tendencies of the blood, and beta blockers are utilized to lower the heart rate and decrease blood pressure. IHD drugs also include calcium channel blockers and ranolazine that improve the efficiency of beta blockers and prevent further progression of coronary disease.

The growing inclination of the masses towards interventional medical procedures along with extensive utilization of anti-anginal medications for the treatment of IHD is one of the key factors driving the market growth. IHD drugs are being incorporated in cardiological treatment procedures such as angioplasty, atherectomy and balloon angioplasty to ensure a healthy recovery and prevent relapse in the future. Additionally, rising consumer awareness regarding the benefits of scheduled administration of these drugs is also creating a significant impact on their demand. Lifestyle habits such as excessive alcohol consumption and smoking along with physical inactiveness are also leading to an increasing prevalence of cardiovascular diseases. Furthermore, the expanding population of geriatrics around the globe, who are severely prone to heart ailments, is also boosting the demand for IHD drugs.

IMARC Group’s latest report provides a deep insight into the global ischemic heart disease (IHD) drugs market covering all its essential aspects. This ranges from macro overview of the market to micro details of the industry performance, recent trends, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc. This report is a must-read for entrepreneurs, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the ischemic heart disease (IHD) drugs market in any manner.

Report Coverage:

Historical, Current and Future Market Trends

Market Breakup by Disease Class:
Angina Pectoris
Myocardial Infarction

Market Breakup by Drug Class:
Anti-Dyslipidemic Drugs
Calcium Channel Blockers
Beta-Blockers
ACE Inhibitors
ARBs
Vasodilators
Antithrombotic Agents

Market Breakup by Region:
North America
Europe
Asia Pacific
Middle East and Africa
Latin America


Competitive Landscape:

The report has also analysed the competitive landscape of the market with some of the key players being AstraZeneca plc, Bayer AG, Eli Lilly, Novartis, Pfizer Inc., Sanofi S.A., Actelion, Baxter International Inc., Boehringer Ingelheim, Bristol-Myers Squibb, Amgen Inc., F.Hoffmann-La Roche, GlaxoSmithKline, Merck, Eisai Co., Ltd., etc.

Key Questions Answered in This Report:

How has the global ischemic heart disease (IHD) drugs market performed so far and how will it perform in the coming years?
What are the key regional markets in the global ischemic heart disease (IHD) drugs industry?
What is the breakup of the market based on the disease class?
What is the breakup of the market based on the drug class?
What are the various stages in the value chain of the global ischemic heart disease (IHD) drugs industry?
What are the key driving factors and challenges in the global ischemic heart disease (IHD) drugs industry?
What is the structure of the global ischemic heart disease (IHD) drugs industry and who are the key players?
What is the degree of competition in the global ischemic heart disease (IHD) drugs industry?


1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Ischemic Heart Disease (IHD) Drugs Market
5.1 Market Overview
5.2 Market Performance
5.3 Market Breakup by Disease Class
5.4 Market Breakup by Drug Class
5.5 Market Breakup by Region
5.6 Market Forecast
6 Market Breakup by Disease Class
6.1 Angina Pectoris
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Myocardial Infarction
6.2.1 Market Trends
6.2.2 Market Forecast
7 Market Breakup by Drug Class
7.1 Anti-Dyslipidemic Drugs
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Calcium Channel Blockers
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Beta-Blockers
7.3.1 Market Trends
7.3.2 Market Forecast
7.4 ACE Inhibitors
7.4.1 Market Trends
7.4.2 Market Forecast
7.5 ARBs
7.5.1 Market Trends
7.5.2 Market Forecast
7.6 Vasodilators
7.6.1 Market Trends
7.6.2 Market Forecast
7.7 Antithrombotic Agents
7.7.1 Market Trends
7.7.2 Market Forecast
8 Market Breakup by Region
8.1 North America
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Europe
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 Asia Pacific
8.3.1 Market Trends
8.3.2 Market Forecast
8.4 Middle East and Africa
8.4.1 Market Trends
8.4.2 Market Forecast
8.5 Latin America
8.5.1 Market Trends
8.5.2 Market Forecast
9 SWOT Analysis
9.1 Overview
9.2 Strengths
9.3 Weaknesses
9.4 Opportunities
9.5 Threats
10 Value Chain Analysis
11 Porters Five Forces Analysis
11.1 Overview
11.2 Bargaining Power of Buyers
11.3 Bargaining Power of Suppliers
11.4 Degree of Competition
11.5 Threat of New Entrants
11.6 Threat of Substitutes
12 Price Analysis
13 Competitive Landscape
13.1 Market Structure
13.2 Key Players
13.3 Profiles of Key Players
13.3.1 AstraZeneca plc
13.3.2 Bayer AG
13.3.3 Eli Lilly
13.3.4 Novartis
13.3.5 Pfizer Inc.
13.3.6 Sanofi S.A.
13.3.7 Actelion
13.3.8 Baxter International Inc.
13.3.9 Boehringer Ingelheim
13.3.10 Bristol-Myers Squibb
13.3.11 Amgen Inc.
13.3.12 F.Hoffmann-La Roche
13.3.13 GlaxoSmithKline
13.3.14 Merck
13.3.15 Eisai Co., Ltd.
List of Figures
Figure 1: Global: Ischemic Heart Disease Drugs Market: Major Drivers and Challenges
Figure 2: Global: Ischemic Heart Disease Drugs Market: Sales Value (in Billion US$), 2013 & 2018
Figure 3: Global: Ischemic Heart Disease Drugs Market: Breakup by Disease Class (in %), 2018
Figure 4: Global: Ischemic Heart Disease Drugs Market: Breakup by Drug Class (in %), 2018
Figure 5: Global: Ischemic Heart Disease Drugs Market: Breakup by Region (in %), 2018
Figure 6: Global: Ischemic Heart Disease Drugs Market Forecast: Sales Value (in Billion US$), 2019-2024
Figure 7: Global: Ischemic Heart Disease Drugs Industry: SWOT Analysis
Figure 8 :Global: Ischemic Heart Disease Drugs Industry: Value Chain Analysis
Figure 9: Global: Ischemic Heart Disease Drugs Industry: Porter’s Five Forces Analysis
Figure 10: Global: Ischemic Heart Disease Drugs (Angina Pectoris) Market: Sales Value (in Million US$), 2013 & 2018
Figure 11: Global: Ischemic Heart Disease Drugs (Angina Pectoris) Market Forecast: Sales Value (in Million US$), 2019-2024
Figure 12: Global: Ischemic Heart Disease Drugs (Myocardial Infarction) Market: Sales Value (in Million US$), 2013 & 2018
Figure 13: Global: Ischemic Heart Disease Drugs (Myocardial Infarction) Market Forecast: Sales Value (in Million US$), 2019-2024
Figure 14: Global: Ischemic Heart Disease Drugs (Anti-Dyslipidemic Drugs) Market: Sales Value (in Million US$), 2013 & 2018
Figure 15: Global: Ischemic Heart Disease Drugs (Anti-Dyslipidemic Drugs) Market Forecast: Sales Value (in Million US$), 2019-2024
Figure 16: Global: Ischemic Heart Disease Drugs (Calcium Channel Blockers) Market: Sales Value (in Million US$), 2013 & 2018
Figure 17: Global: Ischemic Heart Disease Drugs (Calcium Channel Blockers) Market Forecast: Sales Value (in Million US$), 2019-2024
Figure 18: Global: Ischemic Heart Disease Drugs (Beta-Blockers) Market: Sales Value (in Million US$), 2013 & 2018
Figure 19: Global: Ischemic Heart Disease Drugs (Beta-Blockers) Market Forecast: Sales Value (in Million US$), 2019-2024
Figure 20: Global: Ischemic Heart Disease Drugs (ACE Inhibitors) Market: Sales Value (in Million US$), 2013 & 2018
Figure 21: Global: Ischemic Heart Disease Drugs (ACE Inhibitors) Market Forecast: Sales Value (in Million US$), 2019-2024
Figure 22: Global: Ischemic Heart Disease Drugs (ARBs) Market: Sales Value (in Million US$), 2013 & 2018
Figure 23: Global: Ischemic Heart Disease Drugs (ARBs) Market Forecast: Sales Value (in Million US$), 2019-2024
Figure 24: Global: Ischemic Heart Disease Drugs (Vasodilators) Market: Sales Value (in Million US$), 2013 & 2018
Figure 25: Global: Ischemic Heart Disease Drugs (Vasodilators) Market Forecast: Sales Value (in Million US$), 2019-2024
Figure 26: Global: Ischemic Heart Disease Drugs (Antithrombotic Agents) Market: Sales Value (in Million US$), 2013 & 2018
Figure 27: Global: Ischemic Heart Disease Drugs (Antithrombotic Agents) Market Forecast: Sales Value (in Million US$), 2019-2024
Figure 28: North America: Ischemic Heart Disease Drugs Market: Sales Value (in Million US$), 2013 & 2018
Figure 29: North America: Ischemic Heart Disease Drugs Market Forecast: Sales Value (in Million US$), 2019-2024
Figure 30: Europe: Ischemic Heart Disease Drugs Market: Sales Value (in Million US$), 2013 & 2018
Figure 31: Europe: Ischemic Heart Disease Drugs Market Forecast: Sales Value (in Million US$), 2019-2024
Figure 32: Asia Pacific: Ischemic Heart Disease Drugs Market: Sales Value (in Million US$), 2013 & 2018
Figure 33: Asia Pacific: Ischemic Heart Disease Drugs Market Forecast: Sales Value (in Million US$), 2019-2024
Figure 34: Middle East and Africa: Ischemic Heart Disease Drugs Market: Sales Value (in Million US$), 2013 & 2018
Figure 35: Middle East and Africa: Ischemic Heart Disease Drugs Market Forecast: Sales Value (in Million US$), 2019-2024
Figure 36: Latin America: Ischemic Heart Disease Drugs Market: Sales Value (in Million US$), 2013 & 2018
Figure 37: Latin America: Ischemic Heart Disease Drugs Market Forecast: Sales Value (in Million US$), 2019-2024
List of Tables
Table 1: Global: Ischemic Heart Disease Drugs Market: Key Industry Highlights, 2018 and 2024
Table 2: Global: Ischemic Heart Disease Drugs Market Forecast: Breakup by Disease Class (in Million US$), 2019-2024
Table 3: Global: Ischemic Heart Disease Drugs Market Forecast: Breakup by Drug Class (in Million US$), 2019-2024
Table 4: Global: Ischemic Heart Disease Drugs Market Forecast: Breakup by Region (in Million US$), 2019-2024
Table 5: Global: Ischemic Heart Disease Drugs Market Structure
Table 6: Global: Ischemic Heart Disease Drugs Market: Key Players

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report